share_log

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

阿斯利康的ALXN1840显示出治疗铜代谢紊乱的良好效果
Benzinga Real-time News ·  2022/06/23 12:14
  • AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess copper is compromised.
  • The data showed that ALXN1840 met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of care (SoC) arm, including in patients who had been treated previously for an average of 10 years.
  • In the trial, people taking ALXN1840 experienced rapid copper mobilization, with a response at four weeks and sustained through 48 weeks.
  • In patients who were symptomatic at baseline, there were greater improvements in neurological scores for those treated with ALXN1840 compared to SoC. However, there were no significant differences between treatment groups observed at 48 weeks.1 
  • Most trial patients had low baseline symptom scores, so there was minimal room for total score improvement. As people with Wilson's disease experience a highly varied degree of symptoms, this total score may not reflect the extent of disease severity.
  • ALXN1840 was well tolerated, and the long-term safety and efficacy of ALXN1840 are being assessed in an up to 60-month extension period.
  • Price Action: AZN shares are up 1.19% at $64.31 during the market session on the last check Thursday.
  • 阿斯利康纳斯达克公司(Sequoia Capital：AZN)宣布了ALXN1840治疗肝豆状核变性的3期阳性试验的详细结果，该病是一种遗传性疾病，体内清除多余铜的途径受到影响。
  • 数据显示，ALXN1840达到了其主要终点，表明与标准护理(SoC)ARM相比，ALXN1840从组织中的铜动员能力提高了三倍，包括以前接受过平均10年治疗的患者。
  • 在试验中，服用ALXN1840的患者经历了快速的铜动员，在四周起效，并持续到48周。
  • 在基线有症状的患者中，与SOC相比，接受ALXN1840治疗的患者在神经学评分方面有更大的改善。然而，在48周时观察到的治疗组之间没有显著差异。
  • 大多数试验患者的基线症状评分较低，因此总评分改善的空间很小。由于威尔逊病患者的症状程度千差万别，这一总分可能不能反映疾病的严重程度。
  • ALXN1840耐受性良好，ALXN1840的长期安全性和有效性正在进行长达60个月的延长期评估。
  • 价格行动：周四尾盘，AZN股价上涨1.19%，至64.31美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发